Are the MIA and MSKCC nomograms useful in selecting patients with melanoma for sentinel lymph node biopsy?

The Melanoma Institute of Australia (MIA) and Memorial Sloan Kettering Cancer Center (MSKCC) nomograms were developed to help guide sentinel lymph node biopsy (SLNB) decisions. Although statistically validated, whether these prediction models provide clinical benefit at National Comprehensive Cancer Network guideline‐endorsed thresholds is unknown. We conducted a net benefit analysis to quantify the clinical utility of these nomograms at risk thresholds of 5%–10% compared to the alternative strategy of biopsying all patients. External validation data for MIA and MSKCC nomograms were extracted from respective published studies.

• Publication year

  2023

• Venue

  Journal of Surgical Oncology

• Publication date

  2023-03-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/jso.27231PMID 36905337PMCID PMC10147582
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Guidelines and quality criteria for artificial intelligence-based prediction models in healthcare: a scoping review

  2022cited by this paper
• Assessing Performance and Clinical Usefulness in Prediction Models With Survival Outcomes: Practical Guidance for Cox Proportional Hazards Models

  2022cited by this paper
• Assessing performance and clinical usefulness in prediction models with survival outcomes: practical guidance for Cox proportional hazards models

  2022cited by this paper
• Predicting sentinel node positivity in patients with melanoma: external validation of a risk‐prediction calculator (the Melanoma Institute Australia nomogram) using a large European population‐based patient cohort *

  2021cited by this paper
• Improved Risk Prediction Calculator for Sentinel Node Positivity in Patients With Melanoma: The Melanoma Institute Australia Nomogram.

  2020cited by this paper
• External validation of prognostic models: what, why, how, when and where?

  2020cited by this paper
• Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit.

  2020cited by this paper
• NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY

  2019cited by this paper
• A simple, step-by-step guide to interpreting decision curve analysis

  2019cited by this paper
• Reporting and Interpreting Decision Curve Analysis: A Guide for Investigators.

  2018cited by this paper
• Completion Dissection or Observation for Sentinel‐Node Metastasis in Melanoma

  2017cited by this paper
• Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests

  2016cited by this paper
• Assessing the Clinical Impact of Risk Prediction Models With Decision Curves: Guidance for Correct Interpretation and Appropriate Use.

  2016cited by this paper
• Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial.

  2016cited by this paper
• Decision curve analysis.

  2015cited by this paper
• Validation of a nomogram predicting sentinel lymph node status in melanoma in an Irish population

  2015cited by this paper
• Beyond the Usual Prediction Accuracy Metrics: Reporting Results for Clinical Decision Making

  2012cited by this paper
• Prognostic Importance of the Extent of Ulceration in Patients With Clinically Localized Cutaneous Melanoma

  2012cited by this paper
• Maximizing the clinical usefulness of a nomogram to select patients candidate to sentinel node biopsy for cutaneous melanoma.

  2011cited by this paper
• Sentinel-node biopsy or nodal observation in melanoma.

  2006cited by this paper
• A Nomogram That Predicts the Presence of Sentinel Node Metastasis in Melanoma With Better Discrimination Than the American Joint Committee on CancerStaging System

  2005cited by this paper
• Complications Associated With Sentinel Lymph Node Biopsy for Melanoma

  2003cited by this paper
• Tumor Thickness, Level of Invasion and Node Dissection in Stage I Cutaneous Melanoma

  1975cited by this paper

• Validation and clinical utility of predictive nomograms for sentinel node positivity in cutaneous malignant melanoma in Ireland.

  2026cites this paper
• Validation of risk prediction models for sentinel lymph node metastasis in melanoma in a high UV index region

  2025cites this paper
• 31-Gene expression profiling for cutaneous melanoma: an expert consensus panel.

  2025cites this paper
• A prospective, multicenter analysis of the integrated 31-gene expression profile test for sentinel lymph node biopsy (i31-GEP for SLNB) test demonstrates reduced number of unnecessary SLNBs in patients with cutaneous melanoma

  2025cites this paper
• Surgical Management of Thick Primary Cutaneous Melanoma in the US

  2025cites this paper
• Nodal Management in Melanoma: Is Nodal Staging Needed, What Is the Value, and What Is the Extent of Surgery?

  2025cites this paper
• A Prospective, Multicenter Analysis of Recurrence‐Free Survival After Sentinel Lymph Node Biopsy Decisions Influenced by the 31‐GEP

  2025cites this paper
• Development of Nomograms to Predict the Probability of Recurrence at Specific Sites in Patients with Cutaneous Melanoma

  2025cites this paper
• Comparing Two Gene Expression Profile Tests to Standard of Care for Identifying Patients With Cutaneous Melanoma at Low Risk of Sentinel Lymph Node Positivity

  2025cites this paper
• Impact of an online risk prediction tool for sentinel node metastasis on clinical decision-making in melanoma care: A mixed methods study

  2024cites this paper
• Population-Based Validation of the MIA and MSKCC Tools for Predicting Sentinel Lymph Node Status.

  2024cites this paper
• The 31-Gene Expression Profile Test Outperforms AJCC in Stratifying Risk of Recurrence in Patients with Stage I Cutaneous Melanoma

  2024cites this paper
• Validation of the Melanoma Institute of Australia’s Sentinel Lymph Node Biopsy Risk Prediction Tool for Cutaneous Melanoma

  2024cites this paper
• Sentinel lymph node risk prognostication in primary cutaneous melanoma through tissue-based profiling, potentially redefining the need for sentinel lymph node biopsy.

  2024cites this paper
• RE: External validation of the Melanoma Institute Australia Sentinel Lymph Metastasis Risk Prediction Tool using the National Cancer Database.

  2024cites this paper
• Sentinel lymph node positivity in melanoma: Which risk prediction tool is most accurate?

  2024cites this paper
• Are Nomograms Useful for Predicting Sentinel Lymph Node Status in Melanoma Patients?

  2024cites this paper
• Declining Clinical Utility of Tools for Predicting Sentinel Lymph Node Biopsy Status: A Single Institution Experience from 2000 to 2021

  2024cites this paper
• RE: A Clinical Decision Tool to Calculate Pretest Probability of Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma

  2023cites this paper
• Prognostic and predictive biomarkers in melanoma.

  2023cites this paper
• Clinical Utility of Melanoma Sentinel Lymph Node Biopsy Nomograms.

  2023cites this paper
• The Integrated i31-GEP Test Outperforms the MSKCC Nomogram at Predicting SLN Status in Melanoma Patients

  2023cites this paper